Newsfeeds - Spark Newswire

2 minute read

Castle Biosciences Reports Will Be Acquired By Pittsburgh Life Science Greenhouse, No Terms Disclosed

Today, 7:42 PM

Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cernostics, Inc., is being acquired by Castle Biosciences (NASDAQ:CSTL). Cernostics specializes in spatial

CSTL

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Thursday, Sept. 30, 2021: SKLZ, PRLB, TER, NSTG, NTDOY, SE, NXPI, LC, SNAP, ETSY, BMY, CLLS, CRBU, CDXS, NVS, SMFR, CSTL, SDGR

By Michael Horton

Today, 7:42 PM

Skillz (SKLZ) - 15,704 Shares Proto Labs (PRLB) - 7,407 Teradyne (TER) - 16,083 NanoString Technologies (NSTG) - 133,767 Nintendo (NTDOY) - 254,687 Sea (SE) - 80,800 NXP Semiconductors (NXPI) -

BMY

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Monday, Sept. 27, 2021: TER, SNPS, TSLA, TWLO, SMFR, CDXS, CLLS, CSTL, CRBU, NVS, MELI, SE, HEI

By Benzinga Newsdesk

Today, 7:42 PM

Teradyne (TER) - 67,000 Synopsys (SNPS) - 25,099 Tesla (TSLA) - 24,361 Twilio (TWLO) - 31,431 Sema4 Holdings (SMFR) - 1,200 Codexis (CDXS) - 1,200 Cellectis

CDXS

5 minute read

The Daily Biotech Pulse: Cara’s Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal

By Shanthi Rexaline

Today, 7:42 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23)

ABBV

2 minute read

Castle Biosciences Awarded US Federal Supply Schedule Contract For DecisionDx-Melanoma; Size Not Disclosed

By Bill Haddad

Today, 7:42 PM

Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical Centers Castle Biosciences, Inc. (NASDAQ:CSTL), a dermatologic diagnostics company providing personalized

CSTL

1 minute read

News

Castle Biosciences Presents New Data on DecisionDx-Melanoma and DecisionDx-SCC at the 2021 American Academy of Dermatology Summer Meeting

By Benzinga Newsdesk

Today, 7:42 PM

Castle Biosciences, Inc. (NASDAQ:CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced recent presentations on two of its skin cancer gene

CSTL

1 minute read

Castle Biosciences Q2 Earnings Edges Out Expectation On Record Test Report Volume

By Vandana Singh

Today, 7:42 PM

After the market close on Monday, Castle Biosciences Inc (NASDAQ:CSTL) reported that its second-quarter revenues rose 79% Y/Y to $22.75 million,…

CSTL

1 minute read

Castle Biosciences Raises FY21 Sales Guidance From $80M-$83M To $89M-$93M vs $83.64M Est.

By Bill Haddad

Today, 7:42 PM

Castle Biosciences is increasing its previously issued guidance for anticipated total revenue in 2021. The Company now anticipates generating $89-93 million in total revenue in 2021, compared to the

CSTL

1 minute read

Castle Biosciences Q2 EPS $(0.35) Beats $(0.37) Estimate, Sales $22.80M Beat $18.93M Estimate

By Bill Haddad

Today, 7:42 PM

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 337.5 percent decrease over losses of $(0.08) per share from

CSTL

14 minute read

Earnings Scheduled For August 9, 2021

By Benzinga Insights

Today, 7:42 PM

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.

ACM